Can I read Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg^TM^ CMA‐676) on EtoBox?

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg^TM^ CMA‐676) by Maria C. Petti; Maria B. Pinazzi; Daniela Diverio; Atelda Romano; Maria T. Petrucci; Silvia De Santis; Giovanna Meloni; Agostino Tafuri; Franco Mandelli; Francesco Lo Coco is a Medicine article available to read on EtoBox.

What is Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg^TM^ CMA‐676) about?

We report a patient with acute promyelocytic leukaemia (APL) who received two doses of gemtuzumab ozogamicin for advanced disease. Previous treatments included front‐line all‐__trans__ retinoic acid and anthracyclines, polychemotherapy consolidation, salvage chemotherapy for the first relapse followed by autologous stem cell transplantation (ASCT), arsenic trioxide for the second relapse followed by a second ASCT and then high‐dose methotrexate for more advanced systemic disease with central nervous system involvement. The patient achieved prolonged haematological and molecular remission after monotherapy with gemtuzumab ozogamicin given at the time of the third relapse.

Who reads Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg^TM^ CMA‐676)?

Author

Maria C. Petti; Maria B. Pinazzi; Daniela Diverio; Atelda Romano; Maria T. Petrucci; Silvia De Santis; Giovanna Meloni; Agostino Tafuri; Franco Mandelli; Francesco Lo Coco

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0007-1048)

Published

2001

Language

EN

Field

Medicine (Health Sciences)